<DOC>
	<DOCNO>NCT01199887</DOCNO>
	<brief_summary>This open label , Phase One , multicenter study , design evaluate safety , tolerability , explore biologic effect , explore clinical effect follow dos IW001 : 0.1mg/day , 0.5 mg/day , 1.0 mg/day , administer day orally 24 week patient IPF .</brief_summary>
	<brief_title>Trial Of IW001 Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>IW001 therapeutic design treat anti-Col ( V ) -mediated autoimmune disease via oral tolerance . With identification specific antigen involve autoimmune disease process IPF , IW001 induce oral tolerance may effective treatment . IW001 take orally , introduce mucosal immune system Peyer 's Patches distal small intestine , antigen-presenting cell present antigen regulatory T cell ( Tregs ) . These antigen-specific Tregs enter blood stream traffic area specific antigen generate autoimmune response . Thus , IW001 may produce selective suppression immune response Col ( V ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Patients must meet follow include study : 1 . Diagnosis IPF ( ATS criterion ) prior Baseline visit . 2 . Forced Vital Capacity ( FVC ) ≥ 50 % predict . 3 . Lung Diffusion Capacity ( DLCO ) ≥ 35 % predict . 4 . Ages 3575 year inclusive . 5 . Positive antiCol ( V ) antibody . 6 . White blood cell count ( WBC ) ≥ 2500 mm3 . 7 . Hematocrit ≥ 25 % ≤ 59 % . 8 . Platelets ≥ 100,000 mm3 . 9 . Creatinine ≤ 1.5x Upper Limits Normal ( ULN ) . 10 . Bilirubin ≤ 1.5x ULN . 11 . Aspartate aminotransferase ( AST , SGOT ) ≤ 1.5x ULN . 12 . Females childbearing potential ( define less one year postmenopausal surgically sterile ) must use acceptable method birth control practice abstinence time consent sign 30 day treatment discontinuation . If sexually active , female patient must use double barrier method birth control , condom spermicidal . Patient must negative pregnancy test Screening Baseline visit . 13 . Willing able provide adequate write informed consent . Patients exclude study follow : 1 . Concurrent use systemic corticosteroid immunosuppressive within 30 day Baseline visit . 2 . Chronic NSAID use ( limited , i.e. , 72 hour continuous use NSAIDs permit study ) , ( see Section 9 , concomitant medication ) . 3 . Nacetyl cysteine ( NAC ) use within 14 day Baseline visit . 4 . Any disease , condition surgery ( e.g . inflammatory bowel disease , surgical resection ) may cause malabsorption IW001 . 5 . Known suspected allergy bovine product . 6 . Concurrent prior use experimental medication within 30 day Baseline visit . 7 . History smoking within three month prior Baseline visit . 8 . Known Hepatitis C Human Immunodeficiency Virus ( HIV ) infection . 9 . Evidence active infection Baseline visit . 10 . History unstable deteriorate cardiac disease . 11 . Myocardial infarction , coronary artery bypass , angioplasty within 6 month Baseline visit . 12 . Unstable angina pectoris congestive heart failure require hospitalization within 6 month Baseline visit . 13 . Uncontrolled arrhythmia . 14 . Patient history illicit drug alcohol abuse past year current evidence abuse addiction opinion Investigator . 15 . Patient positive finding urine drug screen . 16 . Any clinically significant illness , , opinion Investigator , might put patient risk harm study might adversely affect interpretation study data . 17 . Females pregnant and/or lactate .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>safety , biologic effect , IPF , autoimmune</keyword>
</DOC>